TABLE 5.

Genotypic and phenotypic analysis of GT1b patient viral isolates^a

Dose (mg)	GT or patient	Nadir (h)	NS5A RAM(s) at baseline, first 100 aa (%)	NS5A RAM(s) at nadir, first 100 aa (%)	EDP-239 EC50 (nM)c
					Baseline	Nadir	Fold change
	GT1b (Con1)		Reference	Reference	0.003
10	5404	72	Y93H(4)	L28M(32), L31F(22), P58S(46), Y93H(98)	0.002	0.454	272
	5409	24			0.002	0.002	1
30	5405	12			0.004	0.004	1
	5413b	312		L31M(34)/V(27), P58S(1), A92K(2), Y93C(6)/H(33)/N(2)	0.003	0.071	25
	5414b	72	Y93H(99)	R30Q(7), L31V(7), Y93H(99)	1.2	3.2	3
100	5402	24	R30Q(76)	R30Q(17), Q62P(51), Y93C(1)	0.004	0.003	1
	5406	48			0.002	0.002	1
	5410	12			0.002	0.002	1
200	5403	96	P58S(99)	R30H(53), Y93H(99)	0.002	1.8	809
	5408	24		Y93C(8)	0.002	0.003	1
	5411	12	R30Q(100), Q62R(100)	R30Q(99), Q62R (99)	0.001	0.001	1

^aaa, amino acids.

^bThe viral RNA levels at nadir viral loads for patients 5413 and 5414 were below 1,000 IU/ml, and the sequence could not be amplified; 72 h was selected for patient 5414 and day 14 for patient 5413.

^cn = 2 biological replicates.